GlassScriptPhysician profile
Waheed H Zehri
NPI 1790724185
$2,285.86
in general payments reported to CMS, 2019-2025
24 companies · $369 in 2025
The $369 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94.05 · 2020: $126 · 2021: $169 · 2022: $439 · 2023: $482 · 2024: $606 · 2025: $369.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,458.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,457.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $444.49 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $399.19 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $181.24 | 2019-2024 | Wegovy |
| Amgen INC. | $148.31 | 2024-2025 | Otezla, Repatha, Evenity |
| Boston Scientific Corporation | $148.17 | 2022-2025 | General - Pain Management |
| Inspire Medical Systems, INC. | $123.35 | 2023 | Inspire |
| Janssen Pharmaceuticals, INC | $118.95 | 2021-2023 | Xarelto |
| Glaxosmithkline, LLC. | $118.21 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $74.78 | 2023-2025 | Gvoke Hypopen |
| Abbott Laboratories | $73.96 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Exact Sciences Corporation | $71.85 | 2024-2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $58.50 | 2019-2021 | |
| Pfizer INC. | $52.47 | 2021-2025 | |
| Astellas Pharma US INC | $50.46 | 2023 | Myrbetriq, Veozah |
| E.R. Squibb & Sons, L.L.C. | $40.72 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Itamar Medical INC | $26.33 | 2024 | Watchpatone |
| Daiichi Sankyo INC. | $23.16 | 2024 | Injectafer |
| Corcept Therapeutics | $22.44 | 2023 | Korlym |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.20 | 2025 | Xifaxan |
| Abiomed | $21.19 | 2022 | |
| Digestive Care, INC. | $19.01 | 2024 | Pertzye |
| Bayer Healthcare Pharmaceuticals INC. | $18.55 | 2025 | |
| Novartis Pharmaceuticals Corporation | $14.36 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waheed Zehri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.